HY19 Results Conference Call to take place on Thursday, 22 August 2019 at 3pm CEST
Louvain-la-Neuve, Belgium, 29 July 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today that it will publish its consolidated results for the first half of 2019 on Thursday, 22 August 2019 at 7am CEST.
Conference Call Information
In addition to the press release, Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a conference call and webcast, conducted in English, to present the half year results, followed by a Q&A session.
This conference call will be held on Thursday,22 August 2019 at 3pm CEST / 2pm BST / 9am EDT / 6amPDT and can be accessed online at:
http://arkadinemea-events.adobeconnect.com/iba2208/event/registration.html
If you would like to participate in the Q&A, please dial (PIN code 62997065#):
Belgium: +32 2 403 58 16
UK: +44 20 71 94 37 59
NL: +31 207 09 51 19
LU: +352 2 730 01 63
US: +1 64 67 22 49 16
FR: +33 1 72 72 74 03
The presentation will be available on IBA’s investor relations website and on:
https://iba-worldwide.com/content/half-year-2019-results-press-release-conference-call-details-and-presentation shortly before the call.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has the largest number of installed proton therapy systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at www.iba-worldwide.com
For further information, please contact:
IBA
Soumya Chandramouli
Chief Financial Officer
+32 10 47 58 90
Investorrelations@iba-group.com
Thomas Ralet
Vice-President Corporate Communication
+32 10 47 58 90
communication@iba-group.com
For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Angela Gray, Lizzie Seeley
+44 (0) 20 3709 5700
IBA@consilium-comms.com